Preview

Ateroscleroz

Advanced search

Clinical significance and dynamics of biomarkers of myocardial remodeling in patients with ST segment elevation myocardial infarction and preserved left ventricular function

https://doi.org/10.15372/ATER20180101

Abstract

Objective: to determine the clinical significance of markers of myocardial remodeling (NT-proBNP, galectin-3, sST2, MMP-1, 2, 3 and TIMP-1) in patients with ST segment elevation myocardial infarction and preserved left ventricular function. Materials and methods. 100 consecutive patients diagnosed with ST segment elevation myocardial infarction (STEMI) and LV ejection fraction ≥40 % were included. All patients underwent revascularization of the culprit artery. Echocardiography was performed in all the patients on days 1 day, 10-12 and in a year after hospitalization. In all the patients on admission, days 10-12 and in a year after STEMI serum concentrations of the following markers were assessed: matrix metalloproteinases-1, 2 and 3 (MMP), tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), galectin-3; N-terminal brain natriuretic propeptide (NT-proBNP); soluble protein of the IL-1 receptor family (sST2). Results. The concentration of MMP-3, determined on days 10-12 of the MI, was 1.62 times higher than the values measured on the first day. While the concentration of soluble ST2 receptor, on the contrary, is almost twice as low on days 10-12 as measured on the 1st day. Also statistically significant dynamics in the period of hospitalization was determined for galectin-3 ( p = 0.0001), MMP-2 ( p = 0.0003), NT-proBNP ( p = 0.0361). Analyzing the differences in the concentrations of the markers under study, taking into account the presence / absence of signs of DD, draws attention to the fact of large median values in the group of patients with DD ( n = 38): galectin-3 at each of the observation points, NT-proBNP by the 10-12th day and in a year, MMP-1 - on the 1st and 10-12th day of observation, MMP-2 - at the annual observation stage, MMP-3 - on the 1st and 10-12th days from the MI, TIMP-1 - on the contrary, in the group of patients with DD the concentrations were lower in comparison with patients without DD ( n = 62) both on the 1st day and a year later. For sST2 no significant differences were found. Conclusions. It was determined that in the group of patients with ST segment elevation myocardial infarction and preserved LV function in the hospital period and a year later, a statistically significant dynamics of the majority of studied markers was registered, which indicates the regular processes of structural and functional remodeling of myocardium of the LV at different stages of observation. Significant differences in the levels of studied markers were determined between the groups, taking into account the presence / absence of diastolic dysfunction in patients with preserved and middle fraction of LV ejection.

About the Authors

T. B. Pecherina
Federal State Budgetary Research Institution «Scientific-research Institute for Complex Problems of cardiovascular disease»
Russian Federation


N. V. Fedorova
Federal State Budgetary Research Institution «Scientific-research Institute for Complex Problems of cardiovascular disease»
Russian Federation


A. I. German
Federal State Budgetary Research Institution «Scientific-research Institute for Complex Problems of cardiovascular disease»
Russian Federation


A. G. Chernobay
Federal State Budgetary Research Institution «Scientific-research Institute for Complex Problems of cardiovascular disease»
Russian Federation


T. P. Solodilova
Federal State Budgetary Research Institution «Scientific-research Institute for Complex Problems of cardiovascular disease»
Russian Federation


V. N. Karetnikova
Federal State Budgetary Research Institution «Scientific-research Institute for Complex Problems of cardiovascular disease»
Russian Federation


O. V. Gruzdeva
Federal State Budgetary Research Institution «Scientific-research Institute for Complex Problems of cardiovascular disease»
Russian Federation


O. M. Polikutina
Federal State Budgetary Research Institution «Scientific-research Institute for Complex Problems of cardiovascular disease»
Russian Federation


V. V. Kashtalap
Federal State Budgetary Research Institution «Scientific-research Institute for Complex Problems of cardiovascular disease»
Russian Federation


O. L. Barbarash
Federal State Budgetary Research Institution «Scientific-research Institute for Complex Problems of cardiovascular disease»
Russian Federation


References

1. Lloyd-Jones D., Adams R., Carnethon M. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee // Circulation. 2009 Jan 27. Vol. 119, N 3. P. 21-181.

2. Roger V.L., Weston S.A., Redfield M.M. et al. Trends in heart failure incidence and survival in a community-based population // JAMA. 2004 Jul 21. Vol. 292, N 3. P. 344-350.

3. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016 // Рос. кардиол. журн. 2017. Т. 1 (141). С. 7-81. http://dx.doi.org/10.15829/1560-4071-2017-1-7-81

4. Gazewood J.D., Turner P.L. Heart Failure with Preserved Ejection Fraction: Diagnosis and Management // Am. Fam. Phys. 2017. Nov 1. Vol. 96, N 9. P. 582-588.

5. Tromp J., Mohsin A.F.K., IJsbrand T.K. et al. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction // J. Am. Heart Associat. 2017. N 6. P. e003989

6. Havmöller R., Chugh S.S. Plasma biomarkers for prediction of sudden cardiac death: another piece of the risk stratification puzzle? // Circ. Arrhythm. Electrophys. 2012 Feb. Vol. 5, N 1. P. 237-243.

7. Van Kimmenade R.R., Januzzi J.L.Jr. Emerging biomarkers in heart failure // Clin. Chem. 2012 Jan. Vol. 58, N 1. P. 127-138.

8. Ahmad T., Fiuzat M., Neely B. et. al. Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients with Chronic Heart Failure // JACC Heart Fail. 2014 Jun. Vol. 2, N 3. P. 260-268.

9. Xie P., Cao Y.S., Su P. et al. Expression of toll-like receptor 4, tumor necrosis factor- alpha, matrix metalloproteinase-9 and effects of benazepril in patients with acute coronary syndromes // Clin. Med. Insights Cardiol. 2010. Vol. 4. P. 89-93.

10. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // Eur. Heart J. 2016. Vol. 37. P. 2129-2200.

11. Huttin O., Coiro S., Selton-Suty Ch. et. al. Prediction of Left Ventricular Remodeling after a Myocardial Infarction: Role of Myocardial Deformation: A Systematic Review and Meta-Analysis // PLoS One. 2016. Vol. 11, N 12: e0168349.

12. Huang D., Cheng J.W.M. Pharmacologic Management of Heart Failure with Preserved Ejection Fraction // The Annals of Pharmacotherapy. 2010. Vol. 44, N 12. P. 1933-1945.

13. Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) - Developed with the special contribution of the Heart Failure Association (HFA) of the ESC // Eur. Heart J. 2016. Vol. 37. P. 2129-2200.

14. Sunil Nadar. New Classification for Heart Failure with Mildly Reduced Ejection Fraction // Sultan Qaboos Univ. Med. J. 2017 Feb. Vol. 17, N 1. P. 23-26.

15. Meijers W.C., van der Velde A.R., de Boer R.A. Biomarkers in heart failure with preserved ejection fraction // Neth Heart J. 2016 Apr. Vol. 24, N 4. P. 252-258.

16. Martinez-Rumayor A., Richards A.M., Burnett J.C., Januzzi J.L. Jr. Biology of the natriuretic peptides // Am. J. Cardiol. 2008 Feb 4. Vol. 101, N 3A. P. 3-8.

17. Lubien E., DeMaria A., Krishnaswamy P. et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings // Circulation. 2002. Vol. 105. P. 595-601.

18. Maisel A.S., McCord J., Nowak R.M. et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study // J. Am. Coll. Cardiol. 2003. Vol. 41. P. 2010-2017.

19. Mak G.S, DeMaria A., Clopton P., Maisel A.S. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings // Am. Heart J. Vol. 2004, N 148. P. 895-902.

20. Tschope C., Kasner M., Westermann D. et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements // Eur. Heart J. 2005. Vol. 26. P. 2277-2284.

21. Iwanaga Y., Nishi I., Furuichi S. et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure // J. Am. Coll. Cardiol. 2006. Vol. 47. P. 742-748.

22. Yancy C.W., Jessup M., Bozkurt B. et al. ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines // Circulation. 2013. Vol. 128: e240-e327.

23. de Boer R.A., Lok D.J., Jaarsma T. et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction // Ann. Med. 2011. Vol. 43. P. 60-68.

24. Carrasco-Sanchez F.J., Aramburu-Bodas O., Salamanca-Bautista P. et al. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction // Int. J. Cardiol. 2013. Vol. 169. P. 177-182.

25. Edelmann F., Wachter R., Schmidt A.G. et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial // JAMA. 2013. Vol. 309. P. 781-791.

26. Edelmann F., Holzendorf V., Wachter R. et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial // Eur. J. Heart Fail. 2015. Vol. 17. P. 214-223.

27. Bayes-Genis A., Pascual-Figal D., Januzzi J.L. et. al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure // Rev. Esp. Cardiol. Vol. 63, N 10. P. 1171-1178.

28. Frioes F., Lourenco P., Laszczynska O. et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction // Clin. Res. Cardiol. 2015. Vol. 104. P. 491-499.

29. Manzano-Fernandez S., Mueller T., Pascual-Figal D. et. al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction // Am. J. Cardiol. 2011. Vol. 107. P. 259-267.

30. Johnson J.L. Matrix metalloproteinases and their inhibitors in cardiovascular pathologies: current knowledge and clinical potential. Metalloproteinases // In Medicine. 2014. Vol. 1. P. 21-36.


Review

For citations:


Pecherina T.B., Fedorova N.V., German A.I., Chernobay A.G., Solodilova T.P., Karetnikova V.N., Gruzdeva O.V., Polikutina O.M., Kashtalap V.V., Barbarash O.L. Clinical significance and dynamics of biomarkers of myocardial remodeling in patients with ST segment elevation myocardial infarction and preserved left ventricular function. Ateroscleroz. 2018;14(1):5-15. (In Russ.) https://doi.org/10.15372/ATER20180101

Views: 215


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2078-256X (Print)
ISSN 2949-3633 (Online)